Download
-+ 0.00%
-+ 0.00%
-+ 0.00%
Hansa Biopharma Q3 loss widens 20% to SEK 178.48 million year over year
Share
Listen to the news
Hansa Biopharma Q3 loss widens 20% to SEK 178.48 million year over year
  • Hansa Biopharma’s third-quarter 2026 loss widened 20% year over year to SEK 178.48 million.
  • Revenue rose year over year to SEK 142.99 million, primarily driven by recognition of the SERB upfront payment.
  • September-end cash and cash equivalents climbed year over year to SEK 1.34 billion; the SERB agreement generated EUR 110 million upfront.
  • Imlifidase’s US regulatory decision target date is December 19, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending